203 related articles for article (PubMed ID: 3386031)
1. [Bone scintigraphy, plasma ALP, TAP and PAP in patients with prostatic cancer].
Imamura A; Hoshi H; Jinnouchi S; Samejima M; Watanabe K
Kaku Igaku; 1988 Feb; 25(2):177-81. PubMed ID: 3386031
[No Abstract] [Full Text] [Related]
2. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
[TBL] [Abstract][Full Text] [Related]
3. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase (PAP) in blood by PAP RIA kit "EIKEN" (author's transl)].
Kida T; Higuchi Y
Kaku Igaku; 1981 Aug; 18(7):907-15. PubMed ID: 7321322
[No Abstract] [Full Text] [Related]
5. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
[TBL] [Abstract][Full Text] [Related]
6. [Relation between serum PAP (prostate acid phosphatase) and bone scintigraphy in prostatic cancer].
Aizawa T; Itoh T; Tsujino S; Namiki K; Miki M
Kaku Igaku; 1992 Nov; 29(11):1277-83. PubMed ID: 1484418
[TBL] [Abstract][Full Text] [Related]
7. [What is the use of the radioimmunoassay of prostatic acid phosphatase?].
Luckacs B; Cohen L; Coloby P; Gattegno B; Michel F; Agnes E; Roland J; Thibault P
J Urol (Paris); 1985; 91(4):211-4. PubMed ID: 2410516
[TBL] [Abstract][Full Text] [Related]
8. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
10. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
Kida T; Higuchi Y
Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.
Merrick MV; Ding CL; Chisholm GD; Elton RA
Br J Urol; 1985 Dec; 57(6):715-20. PubMed ID: 4084732
[TBL] [Abstract][Full Text] [Related]
12. A reappraisal of serial isotope bone scans in prostate cancer.
O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF
Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607
[TBL] [Abstract][Full Text] [Related]
13. The role of prostatic acid phosphatase in the investigation and treatment of adenocarcinoma of the prostate.
Bruce AW; Mahan DE
Ann N Y Acad Sci; 1982; 390():110-21. PubMed ID: 6953923
[No Abstract] [Full Text] [Related]
14. [The diagnostic value of serum acid phosphatases in carcinoma of the prostate (author's transl)].
Braun JS; Habig H; Crüsemann D
Urologe A; 1974 Sep; 13(5):236-41. PubMed ID: 4138057
[No Abstract] [Full Text] [Related]
15. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
16. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
Nemoto S; Rinsho K
Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):53-8. PubMed ID: 6539837
[No Abstract] [Full Text] [Related]
17. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
18. Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare".
Mackintosh J; Simes J; Raghavan D; Pearson B
Br J Urol; 1990 Jul; 66(1):88-93. PubMed ID: 2203503
[TBL] [Abstract][Full Text] [Related]
19. [Phosphatases and bone scan in prostatic cancer].
Urrutia M; Montero J; Grade J; Llopis M
Actas Urol Esp; 1977; 1(4):207-12. PubMed ID: 567001
[No Abstract] [Full Text] [Related]
20. Bone imaging and serum phosphatases in prostatic carcinoma.
Bishop MC; Hardy JG; Taylor MC; Wastie ML; Lemberger RJ
Br J Urol; 1985 Jun; 57(3):317-24. PubMed ID: 4005501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]